The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 9.88 — safe zoneOK
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Kymera Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Sanofi Collaboration Arrangement$33.6M
- Gilead Agreement$5.6M
Leadership changes
From Kymera Therapeutics, Inc.'s own filings, the day they're filed.
- Terence Rooney · appointmenteff. 2026-07-27
- Brian R. Adams · Chief Legal Officer · appointmenteff. 2025-09-03
- Ellen Chiniara · Chief Legal Officer · departureeff. 2025-09-03
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-24
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Kymera Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Kymera Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.